Updated results from a phase 1b clinical trial testing an immunotherapy drug called CRS-207 were announced recently. Study results show that CRS-207 given with standard chemotherapy can treat malignant pleural mesothelioma more effectively than chemotherapy alone.

The Remarkable Trial Results

One of the best results to get from a clinical trial is a partial response because it involves all measurable tumors shrinking by at least 30 percent. The trial has resulted in evaluable results from 34 patients. 20 of those patients (59%) had a partial response to the treatment. Most of the remaining patients’ disease was stabilized. Only one patient in the trial experienced progressive disease.

94 percent of patients in this trial were able to stabilize their disease or shrink their tumors.

The standard of care for mesothelioma is a chemotherapy regimen of two drugs called Alimta (pemetrexed) and cisplatin (Platinol). This is the only officially FDA approved treatment for mesothelioma and it has about a 40 percent response rate for patients. This clinical trial uses standard chemotherapy along with CRS-207.

Dr. Thierry Jahan


The results of the study were shared by, Dr. Thierry Jahan, at the 2016 European Lung Cancer Conference (ELCC) in Geneva, Switzerland. Dr. Jahan is a renowned mesothelioma specialist and a professor of medicine at the University of California in San Francisco. He has also played a major role in the development of CRS-207.

How Does CRS-207 Work?

CRS-207 is an immunotherapy drug. Immunotherapy drugs work with a patient’s immune system to fight a disease. Some effective immunotherapy drugs can even train the patient’s immune system to continue to fight that disease after they are no longer taking the drug.

Researchers designed CRS-207 by modifying a type of bacteria called Listeria. Listeria is essentially a bacteria found in food that can cause food poisoning. Researchers were able to alter Listeria to reduce its negative effects in order to create CRS-207 without making patients sick. However, the body still recognizes Listeria as a threat and stimulates the immune system to respond.

An antigen is anything that the immune system recognizes as dangerous and attacks. CRS-207 works because it is made up of two antigens: Listeria and mesothelin. The antigen mesothelin is expressed in high quantities in mesothelioma tumors but expressed very little in healthy cells.

By combining mesothelin and Listeria, CRS-207 teaches the immune system to associate mesothelin with a threat, causing it to attack the mesothelin-expressing cancer.

Getting Involved with Clinical Trials

Phase 1b of the CRS-207 clinical trial is still ongoing but no longer enrolling. However, phase 3 is expected to begin in May. Contact our nurse for more information about joining clinical trials.

If You Liked What You Read

Try Our Free Complete Guide to Fighting Mesothelioma

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

*includes everything you see here

Show Author

    About the Writer, Jamie Iovino

    Jamie Iovino is the senior writer at Mesothelioma Guide. She creates and edits pages to make sure mesothelioma patients and their families receive the newest and most accurate information about mesothelioma.